Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) announced on Monday that the European Medicines Agency (EMA) has accepted its application to expand the use of Nucala (mepolizumab) for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.
If approved, Nucala would become the first biologic with monthly dosing for COPD.
The submission is based on positive results from the Phase III MATINEE trial, which demonstrated a statistically significant reduction in moderate/severe exacerbations with mepolizumab versus placebo. COPD affects over 40 million people in Europe and is a leading cause of hospitalizations and mortality.
GSK continues to advance respiratory treatments, focusing on targeted biologics and inhaled therapies to address underlying disease mechanisms.
Intelligent Bio Solutions strengthens IP with sixth US patent ahead of 2025 market entry
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
Nyxoah receives FDA Approvable Letter for Genio system
Palatin Technologies' PL7737 granted US FDA orphan drug designation
Benuvia Operations receives five-year contract from NIDA
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Sanofi's tolebrutinib receives FDA priority review for multiple sclerosis treatment
GSK's Nucala (Mepolizumab) COPD application accepted by EMA
Agilent xCELLigence technology Supports FDA Approval of AUCATZYL
Journey Medical launches Emrosi for treatment of rosacea
Everest Medicines' EVM14 IND application receives US FDA approval
CStone Pharmaceuticals submits Type II variation application to EMA for sugemalimab